跳至主要内容
临床试验/NCT04922398
NCT04922398Unknown1 期

Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency: A Randomized Controlled Trial

Ahmed Saad1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年6月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
60
试验地点
1
主要终点
FSH hormonal changes

研究概览

简要总结

60 cases with premature ovarian insufficiency will be randomized to either receive PRP or saline injection in their ovaries. Then follow up by hormonal & ultrasound & clinically to monitor any changes

详细描述

In this pilot study, 60 patients will be included. All patients will have a premature ovarian insufficiency (PORs) who meet at least two of the following three Bologna criteria.

The following data will be registered for all the cases: age, weight, height, menstrual history, previous pregnancies and their outcome, no. of living children and age of the youngest, history symptoms, married for how long, infertility duration and whether primary or secondary. Estimation of Antral Follicle Count (AFC) will be done for all the patients by transvaginal ultrasound (TVUS). Finally, a blood sample will be withdrawn for the following lab. Investigations: FSH, LH, E2, AMH, TSH, Prolactin before inclusion of the patients in the study.

A written consent form will be signed by all patients after complete explanation of the procedures and the expectations of the trial. Patients will be randomized into 2 groups (A& B). All will undergo a transvaginal intervention through an ovum pickup needle 17 G for the procedure. The group A consists of 30 patients, who will receive a PRP (autologous platelet-rich plasma injection) with activation with calcium chloride. The group B consists of 30 patients, who will receive a normal saline inj. 0.9% Nacl.

Sample preparation of the PRP:

According to the classification proposed by Ehrenfest, 4 different types of PRP are defined, depending on the content of cells and the presence of fibrin. In regards to the Classification of PRP in this case study, it is used as a commercial type of PRP with the lower concentration (2.5 x 3 times) system, Ycellbio PRP. The process will be carried out under strict aseptic conditions as well as optimum temperature regulations, i.e., 21-24°C. PRP will be prepared according to the manufacturer's guidelines. Draw 1 CC anticoagulant (sodium citrate) into a 20 CC syringe. Coat the inside walls of the syringe with the drawn anticoagulant. Then draw 14 CC blood under complete aseptic condition into a 20 CC syringe. Swing the syringe slowly to mix blood and anticoagulant well. Inject the blood slowly into the Ycellbio tube. Straighten the tube when the blood reaches the Y-funnel. Inject the blood into the Ycellbiotube to the appropriate level as indicated by the lines. Close the Ycellbio tube with silicon stopper using a forceps. Centrifuge at 3500 RPM at time 5 min. After the 5 min. spin, the Buffy coat is well visible. Twist the controller to adjust the height of buffy coat to the marked line. Twist the controller to adjust the height of buffy coat to the marked line. Prepare a 18 G ½ needle and a 3 CC syringe for PRP harvest. Open the silicone stopper using an alcohol soaked cotton. Extract 2.0 CC PRP while slowly swirling the needle in the area of the PRP into a 3 CC syringe. The same process is done for another 3 blood samples to have a total of 8 ml PRP to be used for both ovaries.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •PORs who meet at least two of the following three Bologna criteria
  • •AMH: 0.1-1 ng/ml.

排除标准

  • •ovarian insufficiency due to gonadal dysgenesis and -
  • •chromosomal abnormalities,
  • •immunoglobulin A deficiency,
  • •the use of anticoagulants,
  • •psychotropic medicaments,
  • •psychiatric disorders,
  • •carcinomas or
  • •a history of chronic pelvic pain.
  • •Women with present infection,
  • •haemoglobin lower than 11 g/L or
  • •platelets lower than 150 x 10ʒ/μL were excluded from the study.

研究组 & 干预措施

Group B: saline group

Placebo Comparator

consists of 30 patients, who will receive 4 ml of a normal saline inj. 0.9% Nacl. then injected into each ovary by TVUS.

干预措施: Normal saline (Drug)

Group A: PRP group

Active Comparator

Preparation of PRP sample fro the patient own blood then the volume immediately above the erythrocyte layer was collected. Calcium gluconate in conc. 1:9 will be used as an activator. After activation, in a period less than 2 min, approximately 4 ml of the PRP will be injected into each ovary by TVUS.

干预措施: platelet rich plasma (Biological)

结局指标

主要结局

FSH hormonal changes

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

The changes in the hormones at day 3 of the menstrual cycle: FSH monitored

vaginal ultrasound monitoring of the ovaries

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

monitor the number of antral follicles.

clinical follow up

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

changes in the menstrual cycle by history taking \& questionnaire

LH hormonal changes

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

serum LH at day 3 of the menstrual cycle

E2 hormonal changes

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

serum E2 at day 3 of the menstrual cycle

AMH hormonal changes

时间窗: 3rd day of the 3rd menstrual cycle after the procedure

serum AMH

次要结局

未报告次要终点

研究者

发起方
Ahmed Saad
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ahmed Saad

Assistant professor of obstetrics & gynecology

Benha University

研究点 (1)

Loading locations...

相似试验